Strategies to Reduce Morbidity and Mortality in COPD: A Patient-focused Approach for Integration of Combination and Triple Therapy

Join us for a livestream event on
Twitter, Facebook, or YouTube!


Wednesday, September 29, 2021
7:30-8:15 PM EST



This CME activity is provided by Integrity Continuing Education, Inc.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

This program is being implemented in collaboration with The COPD Foundation.


This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.


Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, many patients receive a delayed diagnosis or remain undiagnosed and face dismal outcomes. Despite the availability of several pharmacologic therapies and continually updated guideline recommendations, COPD is sub-optimally treated in current clinical practice. As a result, patients with COPD are associated with a poor quality of life, with many patients living in discomfort and experiencing debilitating exacerbations. Recently, evidence has demonstrated the utility of dual and triple therapy combinations of agents in reducing exacerbations among patients with COPD and updated guidelines have identified specific patient subsets that can benefit from these approaches. This educational initiative will inform participants regarding the utility of recently published evidence, precision medicine-based approaches, and updated Global Initiative for Chronic Obstructive Lung Disease and American Thoracic Society guidelines to address underdiagnosis and suboptimal treatment of COPD and allow healthcare providers to overcome existing barriers to achieve improved outcomes among patients with COPD.


MeiLan K. Han, MD, MS​
Professor of Medicine
Division of Pulmonary and Critical Care
University of Michigan
Ann Arbor, Michigan


Ramon G. Reyes, MD
Medical Director
Bandera Family Health Care
San Antonio, Texas


This program is intended for pulmonologists, respiratory therapists, and internal medicine physicians, involved in the management of patients with COPD and for acute care clinicians involved in the management of patients with COPD exacerbations.


Upon completion of this educational activity, participants should be able to:

  • Describe updated criteria for the diagnosis of COPD to enable early recognition and improved assessment of disease severity
  • Review updated guidelines and recommendations for the use of combination bronchodilator therapy to optimize treatment and management of COPD
  • Identify strategies like pulmonary rehabilitation and triple therapy combinations for specific patient subsets to reduce morbidity and mortality


Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Global Education Group designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-21-053-L01-P)

 This is a knowledge-based activity.


In order to receive credit for this activity, the participant must take a pretest, view the live broadcast and complete the evaluation form at the end of the program. A statement of credit will be issued only upon submission of a completed activity evaluation form and will be sent to you within four weeks of receipt of the completed evaluation. For Pharmacist/ACPE learners, please check CPE monitor for your credit within 60 days of the activity.


There is no fee for this educational activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or


Integrity Continuing Education and Global Education Group (Global) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty have the following relevant financial relationships with ineligible companies:

MeiLan K. Han, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Merck, Mylan, Sanofi, Verona
Contracted Research: Novartis, Sanofi, Sunovion

Ramon G. Reyes, MD, has no real or apparent conflicts of interest to disclose.

The  Global Education Group  planners and managers have the following relevant financial relationships with ineligible companies:
Rhys Williams, RN, MSN, FNP, Lindsay Borvansky, Andrea Funk, Liddy Knight, and  Ashley Cann, have nothing to disclose.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

The COPD Foundation planners and managers having the following relevant financial relationships with ineligible companies to disclose:

Michael W. Hess
Consultant: Boehringer Ingelheim
Speaker: Boehringer Ingelheim, Olympus, Theravance Biopharma, Vitalograph
Advisory Board: Theravance Biopharma

Ruth Tal-Singer, PhD
Consultant: ENA Respiratory, ImmunoMet, Teva, VOCALIS Health
Board of Directors (unpaid): ENA Respiratory
Shareholder: GSK
Other: GSK – Retiree (October 2019)


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  •  Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


On the day of the program, you may access the event by going to any of the following links:




There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 0.75 AMA PRA Category 1 CME credit(s)™ or 0.75 contact hour. To do so, you must participate in the virtual livestream activity and complete the posttest and evaluation following the event. A statement of credit will be issued within 2 weeks of submission of a completed activity evaluation form.